SLC5A2 and myocardial infarction: In the current review, we discuss the current evidence on the use of SGLT2 inhibitors in special populations, including patients with acute myocardial infarction (AMI), acute HF, right ventricular (RV) failure, with left ventricular assist device (LVAD), and with type 1 diabetes.